The ESMO presentation is a binary catalyst for October 2026. The stand-alone efficacy data will be critical for partnership discussions. Monitor for any pre-ESMO abstract or partnership announcement.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 17 $3.08entry
- T+1 · 4mo ago −4.39%α −4.23% · $2.94
- T+5 · 4mo ago −0.81%α −0.13% · $3.05
- T+20 · 3mo ago +8.62%α +4.17% · $3.34
- T+60 · 5w ago −2.44%α −7.12% · $3.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion will present three-year Phase 2 data for personalized cancer vaccine EVX-01 at ESMO 2026 (Oct 23-27). The third-year data includes a stand-alone therapy cohort, offering insight into EVX-01's effect without anti-PD-1 combination. Prior two-year data showed a 75% ORR and durable responses, but the stock has historically declined on prior neutral reports, suggesting limited market enthusiasm for early-stage data milestones.
Key Facts
- Three-year Phase 2 data for EVX-01 will be presented at ESMO Congress 2026 (Oct 23-27, Madrid).
- Third-year data includes a subset of patients receiving EVX-01 as stand-alone therapy (no anti-PD-1 combination).
- Prior two-year data showed 75% ORR (12/16 patients), 92% durable response at 2 years, and no relapses.
- EVX-01 induced immune response in all patients; 86% of targeted neoantigens generated T-cell responses.
Financial Impact
No financial data provided; clinical-stage company with no revenue.
Risk Factors
- Three-year data may not show incremental benefit over two-year data.
- Stand-alone therapy cohort may have limited sample size, reducing statistical significance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3329028 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers